Experimental and clinical studies of staphylokinase and Fortelyzin®

• Vishlov E.V.
• Alekseeva Ya.V.
• Gerasimets Е.А.
• Markov V.A.

AbstractThe article presents experimental and pilot clinical studies of staphylokinase as the most fibrin-selective thrombolytic. It was shown a high efficacy and safety of bolus-infusion usage of staphylokinase compared to Actilyse® in patients with myocardial infarction with ST-segment elevation (STEMI). However, the authors observed the appearance of anti-staphylokinase neutralizing antibodies in high titers, which was not allowed to use the thrombolytic agent again. The article presents the results of the clinical application of genetically modified nonimmunogenic staphylokinase - thrombolytic agent Fortelyzin®. As a staphylokinase, Fortelyzin has the highest fibrin-selectivity among all the thrombolytics, which allowes to use the smaller doses of the agent (15 mg) and to obtain high values of coronary reperfusion. After the usage of Fortelyzin® the neutralizing antistaphylokinase antibodies didn»t appear. The results of the 4-year monitoring of the Fortelyzin®, covering 4123 patients with STEMI showed its high efficacy, safety and a simple way of usage.

Keywords:myocardial infarction, acute coronary syndrome with ST segment elevation, thrombolysis, Fortelyzin®

All articles in our journal are distributed under the Creative Commons Attribution 4.0 International License (CC BY 4.0 license)